促红细胞生成素通过早产儿血脑脊液屏障的观察

Observation of Erythropoietin Acrossing Blood - Brain Barrier of Premature Infants

目的研究外源性重组人促红细胞生成素(rhu—EPO)能否通过早产儿血脑脊液屏障。方法将胎龄28-35周、体质量<2500g的早产儿随机分为治疗组20例,对照组16例。治疗组给予rhu-EPO750IU/(kg·周).3次/周,隔日1次,疗程2周;对照组按早产儿常规治疗。用酶联免疫法测两组早产儿治疗前后血清、脑脊液EPO浓度。结果1.治疗组治疗2周后血清、脑脊液EPO浓度均明显高于对照组(P均<0.01)。2.治疗组治疗前后血清、脑脊液EPO浓度相比,治疗后明显高于治疗前(P<0.01)。3.对照组血清、脑脊液EPO浓度在2周后同出生时相比均有所降低,但无显著差异(P>0.05)。结论外源性应用rhu—EPO能通过早产儿血脑脊液屏障。

Objective To observe whether recombinant human erythropoietin （rhu - EPO） could cross blood - brain barrier （BBB） of premature infants. Methods Thirty - six premature infants, with gestational age 28 - 35 weeks, birth weight 〈 2500 g, were randornily divided into EPO treatment group and control group, 20 infants were in treatment group, 16 infants were in control group. Infants in treatment group were received rhu - EPO at a dose 750 IU/kg body weight per week, three times a week every other day by intravenous, for 2 weeks. Blood and cerebral spinal fluid （CSF） ,samples were taken before and after 2 weeks treatment in all the infants of 2 groups. The concentration of EPO was assayed by enzyme linked immunosorbent assay （ELISA）. Results 1. The EPO concentrations in serum and CSF after 2 weeks treatment in rhu - EPO treatment group were significantly higher than those of control group（ P 〈 0.01 ）. 2. The EPO concentrations in ,serum and CSF after 2 weeks treatment in rhu - EPO treatment group were significantly higher than those of before treatment （P〈0.01 ）. 3. The EPO concentrations decreased both in ,serum and CSF in control group after 2 weeks later compared with those of 2 weeks ago, but there was no statistical difference （P〉0.05）. Conclusion Rhu - EPO can cross the BBB of premature infants.